58160-95-5
Chemical Structure
N-Propargylglycine
- CAS No.: 58160-95-5
- Formula:C5H7NO2
- Molecular Weight:113.11
IUPAC Name: prop-2-yn-1-ylglycine
InChIKey: XSJLQGMTIHCDSS-UHFFFAOYSA-N
SMILES: O=C(O)CNCC#C
Biological Activity: N-Propargylglycine is a brain-penetrant and orally active PRODH inhibitor. N-Propargylglycine covalently modifies enzyme-bound FAD and active site lysine, causing enzyme structural distortion, protein decay, and irreversible inhibition of proline and 4-hydroxyproline catabolism. N-Propargylglycine induces UPRmt, upregulates mitochondrial chaperones and YME1L1, enhances mitochondrial proteostasis, blocks astrocytic L-proline consumption, and abolishes L-proline’s ATP-maintaining and viability-protective effects. N-Propargylglycine stimulates neural processes, increases brain proline, hydroxyproline, and sarcosine levels, partially normalizes Huntington’s disease whole brain transcriptomes. N-Propargylglycine reduces hyperoxaluria, prevents calcium oxalate stone formation, reduces kidney tubular damage, and restores weight and survival in Grhpr knockout mice. N-Propargylglycine can be used for the research of breast cancer, neurodegenerative disorders, Huntington’s disease, and primary hyperoxaluria type 2[1][2][3][4][5].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
N-Propargylglycine | 99.70% | N-Propargylglycine is a brain-penetrant and orally active PRODH inhibitor. N-Propargylglycine covalently modifies enzyme-bound FAD and active site lysine, causing enzyme structural distortion, protein decay, and irreversible inhibition of proline and 4-hydroxyproline catabolism. N-Propargylglycine induces UPRmt, upregulates mitochondrial chaperones and YME1L1, enhances mitochondrial proteostasis, blocks astrocytic L-proline consumption, and abolishes L-proline’s ATP-maintaining and viability-protective effects. N-Propargylglycine stimulates neural processes, increases brain proline, hydroxyproline, and sarcosine levels, partially normalizes Huntington’s disease whole brain transcriptomes. N-Propargylglycine reduces hyperoxaluria, prevents calcium oxalate stone formation, reduces kidney tubular damage, and restores weight and survival in Grhpr knockout mice. N-Propargylglycine can be used for the research of breast cancer, neurodegenerative disorders, Huntington’s disease, and primary hyperoxaluria type 2. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
-
Similarity Score 0.82
HY-Y12304-Pentynoic acid -
Similarity Score 0.81
HY-W141879N-Ethylglycine -
Similarity Score 0.80
HY-W004784R3-Butynoic acid (Standard) -
Similarity Score 0.80
HY-Y09255-Hexynoic acid -
Similarity Score 0.78
HY-W141891N-(2-Cyanoethyl)glycine -
Similarity Score 0.78
HY-W0128832-((2-Aminoethyl)amino)acetic acid -
Similarity Score 0.77
HY-346436-Heptynoic acid -
Similarity Score 0.75
HY-W012683RIminodiacetic acid (Standard) -
Similarity Score 0.75
HY-W077223(3-Aminopropyl)glycine -
Explore the MedChemAI to find more analogs
References
- [1]. Scott GK, et al. N-Propargylglycine: a unique suicide inhibitor of proline dehydrogenase with anticancer activity and brain-enhancing mitohormesis properties. Amino Acids. 2021;53(12):1927-1939. [Content Brief]
- [2]. Spellerberg P, et al. Consumption of L-Proline as Energy Substrate by Cultured Primary Rat Astrocytes. Neurochem Res. 2025;51(1):1. Published 2025 Nov 26. [Content Brief]
- [3]. Teramayi F, et al. Brain transcriptomic, metabolic and mitohormesis properties associated with N-propargylglycine treatment: A prevention strategy against neurodegeneration. Brain Res. 2024;1826:148733. [Content Brief]
- [4]. Bons J, et al. Therapeutic targeting of HYPDH/PRODH2 with N-propargylglycine offers a Hyperoxaluria treatment opportunity. Biochim Biophys Acta Mol Basis Dis. 2024;1870(1):166848. [Content Brief]
- [5]. Hady M, et al. N-Propargylglycine Restores Survival by Preventing Calcium Oxalate Stone Formation, Tubular Injury, and Kidney Dysfunction in a Lethal Mouse Model of Primary Hyperoxaluria Type 2. Kidney Int. Published online March 20, 2026. [Content Brief]
